Theraclion announces study in non-invasive varicose vein treatment and the launch of a capital increase through a private placement
The ongoing clinical trial investigates the Echopulse® device for the treatment of insufficient superficial and perforating veins of the lower limb (varicose veins)
· Theraclion launches a capital increase through private placement with institutional investors for a minimum amount of approximately 3 million euros to fund the clinical trials
· In parallel, the funds managed by Truffle Capital will sell at least 177,726 Theraclion shares for the benefit of qualified investors by way of block sale and lock-up commitment for 12 months
THERACLION announced that a clinical trial is currently investigating the use of its Echopulse® device to treat insufficient superficial
and perforating veins of the lower limb (varicose veins) with non-invasive High Intensity Focused Ultrasound (HIFU), also called echotherapy. To fund the trials and other on-going strategic developments, Theraclion announces today the launch of a capital increase with cancellation of preferential subscription rights, in favor of qualified investors through a private placement for a minimum total proceed of approximately 3 million euros.